Dr. Ghobadi on the Potential Development of CAR T Cells in Solid Tumors

Video

Armin Ghobadi, MD, assistant professor of medicine, Division of Medical Oncology, Washington University School of Medicine, Siteman Cancer Center, discusses the potential development of chimeric antigen receptor (CAR) T cells in solid tumors.

Armin Ghobadi, MD, assistant professor of medicine, Division of Medical Oncology, Washington University School of Medicine, Siteman Cancer Center, discusses the potential development of chimeric antigen receptor (CAR) T cells in solid tumors.

Although CAR T-cell therapy has made a big impact in hematologic malignancies, researchers need to focus on finding better targets if the therapy is to transition to solid tumor oncology, explains Ghobadi. Currently, CAR T cells target an antigen that is expressed on the surface of the tumor cell. Refinements to the therapy may enable CAR T cells to target an antigen that is not as visible to CAR T cells.

The biggest challenge with solid tumors is the negative inhibitory environment that prevents the function and penetration of CAR T cells in the tumor microenvironment, says Ghobadi. There is a lot of research in that area, such as making CAR T cells resistant against the negative environment or converting a negative inhibitory receptor to a receptor that activates CAR T cells, states Ghobadi.

Related Videos
Daniel Hart, PhD, on CRISPR-Mediated, In Vivo Epigenomic Activation
Luke Roberts, MBBS, PhD, on Developing Gene Therapy for Congestive Heart Failure
PJ Brooks, PhD, on Improved Newborn Screening, Non-Viral Gene Editing: New Frontiers for Neuromuscular Disease
Sowmya Viswanathan, PhD, on Translating Cell Therapies to the Clinic at ISCT 2024
Omar Nadeem, MD, on Initial Efficacy of GPRC5D-CAR in R/R Multiple Myeloma
Omer A. Abdul Hamid, MD, on Improving Gene Therapy’s Effect and Accessibility
George Tachas, PhD, on Tackling DMD Treatment From Multiple Angles
David Suhy, PhD, the cofounder and chief scientific officer of Earli
Deepak L. Bhatt, MD, MPH, MBA, on Incorporating AI into Genetic Research for Cardiovascular Disease
Jeffrey Chamberlain, PhD, on Helping Progress Cell and Gene Therapy Development
© 2024 MJH Life Sciences

All rights reserved.